C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome
ConditionCOVID-19
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.
Eligibility criteria
Qualifiers
Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine & Health Section or approval by MAGPIES research group.
Be able to participate fully in all aspects of the study.
Have understood and signed study informed consent.
Disqualifiers
Lacking the capacity to consent.
Prisoners and institutionalized individuals.
Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.
Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
Trial design
Treatments tested in this trial
- C11 ER176 Tracer
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov